Orchestra BioMed Holdings, Inc. (OBIO) stock
Close on Nov 12, 2026Market cap $369.65MP/E –Yield –
Orchestra BioMed Holdings, Inc. grew revenue 1007.4% to $31.21M over the twelve months to Sep 30, 2026. Free cash flow was -$64.18M. At the latest close the market valued the company at $369.65M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $369.65M
- P/E ratio
- –
- Price to sales
- 11.85
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -17.36%
Fundamentals
- Revenue
- $31.21M
- Net income
- -$56.95M
- EPS, diluted
- -$0.91
- Free cash flow
- -$64.18M
- Diluted shares
- 65M
Trading
- Previous close
- $6.01
- Open
- $5.99
- Day's range
- $5.70 – $6.18
- Volume
- 631,083
- Average volume (20 days)
- 483,382
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 0.80
- 52-week range
- $3.46 – $6.50
- RSI (14 days)
- 55.6
- Volatility (1 year)
- 64.1%
- Relative volume
- 1.37×
- WACC
- 8.9%
On 2 of our idea lists: Insider cluster buys, Institutions accumulating
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | OBIO | S&P 500 | Difference | OBIO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +4.1% | -2.7% | +6.8 pts | ||
| 3 months | +39.1% | -1.7% | +40.9 pts | ||
| Year to date | +48.2% | +11.9% | +36.3 pts | ||
| 1 year | +39.1% | +12.0% | +27.2 pts | ||
| 3 years | +16.7% | +78.2% | −61.5 pts | +5.3% | +21.2% |
| 5 years | -37.6% | +73.2% | −110.9 pts | -9.0% | +11.6% |
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Orchestra BioMed filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- News
- Update
About Orchestra BioMed
Surgical & Medical Instruments & Apparatus
Orchestra BioMed Holdings, Inc. is a biomedical innovation company focused on developing therapeutic medical technologies through risk-and-reward sharing partnerships with major global medical device companies. The company operates across two principal product development platforms: bioelectronic therapies and interventional devices. Its flagship bioelectronic candidate, Atrioventricular Interval Modulation (AVIM) Therapy, is an algorithmic, firmware-integrated treatment for uncontrolled hypertension in cardiac pacemaker patients, being co-developed under an exclusive global license and collaboration with Medtronic. Its lead interventional candidate, the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB), is a drug-device combination delivering an extended-release sirolimus formulation for treating atherosclerotic artery disease, specifically targeting coronary in-stent restenosis and related vascular conditions.
Company profile, executives and historyOrchestra BioMed stock: common questions
What is Orchestra BioMed's stock price?
OBIO closed at $6.15 on Nov 12, 2026, up 2.33% on the day. Over the past 52 weeks it traded between $3.46 and $6.50.
What is Orchestra BioMed's market cap?
Orchestra BioMed was worth $369.65M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is OBIO's P/E ratio?
Orchestra BioMed lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.91), so it has no meaningful P/E ratio.
How much revenue does Orchestra BioMed make?
Orchestra BioMed reported revenue of $31.21M for the twelve months to Sep 30, 2026, up 1007.4% from a year earlier.
Does Orchestra BioMed pay a dividend?
No. Orchestra BioMed has not paid a cash dividend over the last twelve months.
How has OBIO stock performed over the past year?
Including dividends, OBIO returned +39.1% over the past year, against +12.0% for the S&P 500.
How many OBIO shares are sold short?
3M shares were sold short at the latest FINRA report, 10.48% of the float, or 7.0 days of average trading volume.
Who are Orchestra BioMed's competitors?
Companies most similar to Orchestra BioMed by business, industry and size include CVRX, CLPT, BWAY, BDMD, PLSM.
See a number that looks wrong?